Search results
Results from the WOW.Com Content Network
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. Department of Health and Human Services (HHS) office responsible for the procurement and development of medical countermeasures, principally against bioterrorism, including chemical, biological, radiological and nuclear (CBRN) threats, as well as pandemic influenza and emerging diseases.
Assistant Secretary of Defense (Nuclear, Chemical & Biological Defense Programs) Andrew C. Weber: January 7, 2011 – October 1, 2014: Robert M. Gates Leon Panetta Chuck Hagel: Barack Obama: Dr. A Thomas Hopkins (Acting) October 1, 2014 – November 29, 2017 Ash Carter: Barack Obama: Guy B. Roberts: November 30, 2017 – April 2, 2019: Jim ...
Ology Bioservices (previously named Nanotherapeutics, Inc.) is a private, American biopharmaceutical company headquartered in Alachua, Florida.The company was founded with research in nanometer-scale particle technology to develop new drug delivery technologies and increase the efficacy of existing drugs. [3]
Fourteen of 25 analysts following the stock have a “buy” or “strong buy” rating on L3Harris stock, with an average price target of $274.27. Pros and Cons of Defense Stocks
(Reuters) -Medtronic slightly lifted the lower end of its annual profit forecast on Tuesday, banking on sustained demand for its medical devices and growth from its new launches, sending its ...
The Medical CBRN (Chemical, Biological, Radiological and Nuclear) Defense Consortium, a DOD initiative within its Joint Program Executive Office for Chemical and Biological Defense has awarded the company US$20 million to develop an auto-injector to administer diazepam.
CBRN incidents are responded to under the assumption that they are intentional and malicious; evidence preservation and perpetrator apprehension are of greater concern than with Hazmat team incidents. A 2011 forecast concluded that worldwide government spending on CBRN defense products and services would reach US$8.38 billion that year. [1]
The joint-implant maker raised the lower end of its profit forecast to $10.35 from 10.25 per share, while keeping the top-end of the range unchanged at $10.45. ... Sales at Stryker's medical ...